Zenocutuzumab, a HER2xHER3 Biclonics® Antibody That Can Overcome HER3 Mediated NRG1 Signaling In Tumor Cells By Docking On HER2
Time: 9:00 am
day: Day Two
Details:
- Uncovering Merus’ bispecific antibody screening platform to identify novel Biclonics and Triclonics antibodies
- Detection of NRG1 fusions & therapeutic targeting of NRG1 fusion positive patients, a biomarker-driven rare entity (with a significant unmet medical need)
- Zenocutuzumab shows Robust and Durable Responses in NRG1+ Cancer
